News

The trial is one of the two phase 1 safety clinical studies of the drug examining its potential to cause dermal irritation. XF-73 is Destiny Pharma’s lead candidate

The study achieved its primary endpoint at the first pre-specified interim analysis, with Alunbrig showing a statistically significant improvement in PFS compared against crizotinib in adults with anaplastic

The company will build the new multi-storey and 400,000ft² production facility in Portage, situated in Kalamazoo County. Named as modular aseptic processing (MAP), the new production facility will

The proof-of-concept study will assess the efficacy and safety of sulfatinib as a monotherapy in patients with advanced BTC, whose condition has progressed on standard first-line chemotherapy, and

TRX518 is a humanized monoclonal antibody with agonist activity that has been designed to target the glucocorticord-inducible TNF-superfamily receptor (GITR). The GITR agonist has been engineered to improve

The acquisition will allow Cambrex to enter the dosage form CDMO market. Halo Pharma is majority owned by funds managed by the private investment firm SK Capital Partners.

Tibsovo, which is an oral and targeted inhibitor of the IDH1 enzyme, is said to be the first and only FDA-approved therapy for patients with R/R AML and

The primary endpoint of the trial was defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE). Tradjenta had shown similar

Under the deal, Novartis will acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Based on the achievement of